insulin glulisine

(redirected from Apidra)
Also found in: Medical.

insulin glu·li·sine

 (glo͞o′lĭ-sēn′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of lysine for asparagine and glutamic acid for lysine in the B chain, used in the treatment of type 1 and type 2 diabetes.

[glu(tamic acid) + alteration of lysine.]
References in periodicals archive ?
com/report/human-insulin-market#customization Human Insulin Market Segmentation: By Type: Modern Human Insulin o Rapid Acting o Long Acting o Premixed Modern Traditional Human Insulin o Short Acting o Intermediate Acting o Premixed Traditional By Brand: Modern Human Insulin Brands o Apidra o Humalog o Levemir o NovoRapid o NovoMix o Lantus By Region: North America o U.
The product, which delivers 1 to 30 units per injection, can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin).
This product is in adjacent space to Sanofi's top selling Lantus and Apidra insulin products that also are available in the form of SoloSTAR injection pens.
This product is in an adjacent space to Sanofi's top selling Lantus and Apidra insulin products that also are available in the form of SoloSTAR injection pens.
Diversified healthcare company Sanofi (Euronext:SAN) on Friday reported data from a 60-week, open-label study, the 'All to Target' study, that evaluated two Lantus and Apidra regimens as compared with premixed regimen for treatment of uncontrolled type 2 diabetes.
6% increase in second-quarter profit on higher sales of its Lantus and Apidra diabetes treatments.
Launched initially in Australia, and now worldwide, the product dispenses the famous Lantus long-lasting insulin, as well as the shorter-acting Apidra brand.
The Food and Drug Administration approved a new pediatric indication for Apidra (insulin glulisine [rDNA origin] solution for injection).
The approval is based upon review of a 26-week, phase III, open-label, active control study of APIDRA A in comparison with HumalogA (both administered pre-meal) in 572 children and adolescents with Type 1 diabetes.
European Commission has approved Apidra, a rapid-acting insulin analog for the control of hyperglycemia in adolescents and children with diabetes, Sanofi-aventis has announced.
Humulin and Humalog mixes are good for ten days after first use; NPH and Novolog for 14 days; and Humalog, Novolog, Apidra, and Lantus for 28 days.
Patient share estimates further reveal that preferences for short-acting analogues vary between surveyed countries but that Novo Nordisk's Novolog/NovoRapid and Eli Lilly's Humalog are more frequently used than Sanofi's Apidra.